| Phoenix Neurology And Sleep Medicine Pllc | |
|
2940 N Litchfield Rd Goodyear AZ 85395-7830 | |
| (623) 535-0050 | |
| (623) 535-9620 |
| Full Name | Phoenix Neurology And Sleep Medicine Pllc |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 2940 N Litchfield Rd, Goodyear, Arizona |
| Authorized Official Name and Position | Troy G Anderson (MANAGING MEMBER) |
| Authorized Official Contact | 6235350050 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Phoenix Neurology And Sleep Medicine Pllc Po Box 205112 Dallas TX 75320-5112 Ph: (623) 535-0050 | Phoenix Neurology And Sleep Medicine Pllc 2940 N Litchfield Rd Goodyear AZ 85395-7830 Ph: (623) 535-0050 |
| NPI Number | 1285687822 |
|---|---|
| Provider Enumeration Date | 05/17/2006 |
| Last Update Date | 08/13/2014 |
| Medicare PECOS PAC ID | 9335152669 |
|---|---|
| Medicare Enrollment ID | O20060803000031 |
News Archive
Children and adolescents injured in motor vehicle accidents have better outcomes when treated at a stand-alone Level I pediatric trauma center (PTC) than at general adult trauma centers (ATC) or adult trauma centers with added Level I pediatric qualifications (ATC+PTC), according to a new study to be published in the Journal of Pediatric Surgery by researchers from Children's Minnesota.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."
Illumina, Inc. today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List.
Alimera Sciences, Inc. (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285687822 | NPI | - | NPPES |
| 918581 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | (* (Not Available)) | Primary |
| Provider Name | Julius R Charlie |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1063479707 PECOS PAC ID: 9638149966 Enrollment ID: I20040726001317 |
News Archive
Children and adolescents injured in motor vehicle accidents have better outcomes when treated at a stand-alone Level I pediatric trauma center (PTC) than at general adult trauma centers (ATC) or adult trauma centers with added Level I pediatric qualifications (ATC+PTC), according to a new study to be published in the Journal of Pediatric Surgery by researchers from Children's Minnesota.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."
Illumina, Inc. today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List.
Alimera Sciences, Inc. (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
| Provider Name | Susan A Scott |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457497604 PECOS PAC ID: 7911972948 Enrollment ID: I20040901000607 |
News Archive
Children and adolescents injured in motor vehicle accidents have better outcomes when treated at a stand-alone Level I pediatric trauma center (PTC) than at general adult trauma centers (ATC) or adult trauma centers with added Level I pediatric qualifications (ATC+PTC), according to a new study to be published in the Journal of Pediatric Surgery by researchers from Children's Minnesota.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."
Illumina, Inc. today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List.
Alimera Sciences, Inc. (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
| Provider Name | Troy G Anderson |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1710958947 PECOS PAC ID: 5395782296 Enrollment ID: I20050412001185 |
News Archive
Children and adolescents injured in motor vehicle accidents have better outcomes when treated at a stand-alone Level I pediatric trauma center (PTC) than at general adult trauma centers (ATC) or adult trauma centers with added Level I pediatric qualifications (ATC+PTC), according to a new study to be published in the Journal of Pediatric Surgery by researchers from Children's Minnesota.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."
Illumina, Inc. today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List.
Alimera Sciences, Inc. (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
| Provider Name | Kimberly D Vana |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1407947104 PECOS PAC ID: 8921024134 Enrollment ID: I20051018000121 |
News Archive
Children and adolescents injured in motor vehicle accidents have better outcomes when treated at a stand-alone Level I pediatric trauma center (PTC) than at general adult trauma centers (ATC) or adult trauma centers with added Level I pediatric qualifications (ATC+PTC), according to a new study to be published in the Journal of Pediatric Surgery by researchers from Children's Minnesota.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."
Illumina, Inc. today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List.
Alimera Sciences, Inc. (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
| Provider Name | Daniel T Torzala |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1437127990 PECOS PAC ID: 0446303689 Enrollment ID: I20090805000257 |
News Archive
Children and adolescents injured in motor vehicle accidents have better outcomes when treated at a stand-alone Level I pediatric trauma center (PTC) than at general adult trauma centers (ATC) or adult trauma centers with added Level I pediatric qualifications (ATC+PTC), according to a new study to be published in the Journal of Pediatric Surgery by researchers from Children's Minnesota.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."
Illumina, Inc. today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List.
Alimera Sciences, Inc. (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
| Provider Name | Eric J Foltz |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1063550978 PECOS PAC ID: 5294826855 Enrollment ID: I20101004000960 |
News Archive
Children and adolescents injured in motor vehicle accidents have better outcomes when treated at a stand-alone Level I pediatric trauma center (PTC) than at general adult trauma centers (ATC) or adult trauma centers with added Level I pediatric qualifications (ATC+PTC), according to a new study to be published in the Journal of Pediatric Surgery by researchers from Children's Minnesota.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."
Illumina, Inc. today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List.
Alimera Sciences, Inc. (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
| Provider Name | Shruti Badhwar |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1497918502 PECOS PAC ID: 0244406593 Enrollment ID: I20120109000238 |
News Archive
Children and adolescents injured in motor vehicle accidents have better outcomes when treated at a stand-alone Level I pediatric trauma center (PTC) than at general adult trauma centers (ATC) or adult trauma centers with added Level I pediatric qualifications (ATC+PTC), according to a new study to be published in the Journal of Pediatric Surgery by researchers from Children's Minnesota.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."
Illumina, Inc. today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List.
Alimera Sciences, Inc. (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
| Provider Name | Albert L Klaski |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1619132792 PECOS PAC ID: 1254596075 Enrollment ID: I20120629000151 |
News Archive
Children and adolescents injured in motor vehicle accidents have better outcomes when treated at a stand-alone Level I pediatric trauma center (PTC) than at general adult trauma centers (ATC) or adult trauma centers with added Level I pediatric qualifications (ATC+PTC), according to a new study to be published in the Journal of Pediatric Surgery by researchers from Children's Minnesota.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."
Illumina, Inc. today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List.
Alimera Sciences, Inc. (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
| Provider Name | Harpreet K Sandhu |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1215135462 PECOS PAC ID: 3173772449 Enrollment ID: I20130529000693 |
News Archive
Children and adolescents injured in motor vehicle accidents have better outcomes when treated at a stand-alone Level I pediatric trauma center (PTC) than at general adult trauma centers (ATC) or adult trauma centers with added Level I pediatric qualifications (ATC+PTC), according to a new study to be published in the Journal of Pediatric Surgery by researchers from Children's Minnesota.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."
Illumina, Inc. today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List.
Alimera Sciences, Inc. (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
| Provider Name | Amparo E Macariola |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1932505401 PECOS PAC ID: 3971884669 Enrollment ID: I20201013003109 |
News Archive
Children and adolescents injured in motor vehicle accidents have better outcomes when treated at a stand-alone Level I pediatric trauma center (PTC) than at general adult trauma centers (ATC) or adult trauma centers with added Level I pediatric qualifications (ATC+PTC), according to a new study to be published in the Journal of Pediatric Surgery by researchers from Children's Minnesota.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."
Illumina, Inc. today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List.
Alimera Sciences, Inc. (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
News Archive
Children and adolescents injured in motor vehicle accidents have better outcomes when treated at a stand-alone Level I pediatric trauma center (PTC) than at general adult trauma centers (ATC) or adult trauma centers with added Level I pediatric qualifications (ATC+PTC), according to a new study to be published in the Journal of Pediatric Surgery by researchers from Children's Minnesota.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."
Illumina, Inc. today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List.
Alimera Sciences, Inc. (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
Nrt Support Services Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 15526 W Rio Vista Ln, Goodyear, AZ 85338 Phone: 480-516-6081 | |
Trauma Recovery Services Of Arizona, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2990 N Litchfield Rd Ste 7, Goodyear, AZ 85395 Phone: 623-300-1237 Fax: 623-335-0404 | |
Dream Land Mental Health Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1300 S Litchfield Rd, Goodyear, AZ 85338 Phone: 602-529-0706 | |
Adora Healthcare Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4725 N 152nd Dr, Goodyear, AZ 85395 Phone: 216-544-5418 | |
Abcs Of Autism Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 18103 W Illini St, Goodyear, AZ 85338 Phone: 951-313-7203 | |
Mk Life Counseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1755 N Pebble Creek Pkwy, Goodyear, AZ 85395 Phone: 623-455-6015 | |
Divergent Recovery Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 15655 W Roosevelt St Ste 100, Goodyear, AZ 85338 Phone: 480-336-0507 |